All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
October 2024: Finerenone reclassified to amber (specialist only)
News
October 2024: Finerenone reclassified to amber (specialist only)
Finerenone 10mg and 20mg tablets have been reclassified to amber (specialist input) in the Devon Formulary for use in stage 3 and 4 chronic kidney disease (with an albumin to creatinine ratio that is persistently 3mg/mmol or more and eGFR of 25ml/min/1.73m2 or more) associated with type 2 diabetes in line with NICE TA877.
- Finerenone is only recommended as an add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of:
- angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and
- sodium–glucose cotransporter 2 (SGLT2) inhibitors.
- The specialist will start treatment with finerenone, prescribe, and monitor until the dose is stabilised.
See here for the formulary entry.
